GluBio has established a proprietary TPD discovery platform which enables a robust screening capability. The firm is advancing a diverse pipeline of highly selective small-molecule degraders across multiple therapeutic areas including oncology and immunology.

In August 2022, the company completed a Series A+ financing of $22 million which will accelerate the execution of GluBio's pipeline and platform.